Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

View/ Open
Author
Stürmer, Til
Marquis, M. Alison
Zhou, Haibo
Lim, Soo
Blonde, Lawrence
MacDonald, Eileen
Wang, Ray
LaVange, Lisa M.
Pate, Virginia
Buse, John B.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.2337/dc13-0263Metadata
Show full item recordCitation
Stürmer, T., M. A. Marquis, H. Zhou, J. B. Meigs, S. Lim, L. Blonde, E. MacDonald, et al. 2013. “Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin.” Diabetes Care 36 (11): 3517-3525. doi:10.2337/dc13-0263. http://dx.doi.org/10.2337/dc13-0263.Abstract
OBJECTIVE To add to the evidence on comparative long-term effects of insulin analog glargine versus human NPH insulin on the risk for cancer. RESEARCH DESIGN AND METHODS We identified cohorts of initiators of glargine and human NPH without an insulin prescription during the prior 19 months among patients covered by the Inovalon Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry) between January 2003 and December 2010. Patients were required to have a second prescription of the same insulin within 180 days and to be free of cancer. We balanced cohorts on risk factors for cancer outcomes based on comorbidities, comedication, and health care use during the prior 12 months using inverse probability of treatment weighting. Incident cancer was defined as having two claims for cancer (any cancer) or the same cancer (breast, prostate, colon) within 2 months. We estimated adjusted hazard ratios (HRs) and their 95% CI using weighted Cox models censoring for stopping, switching, or augmenting insulin treatment, end of enrollment, and mortality. RESULTS More patients initiated glargine (43,306) than NPH (9,147). Initiators of glargine (NPH) were followed for 1.2 (1.1) years and 50,548 (10,011) person-years; 993 (178) developed cancer. The overall HR was 1.12 (95% CI 0.95–1.32). Results were consistent for breast cancer, prostate cancer, and colon cancer; various durations of treatment; and sensitivity analyses. CONCLUSIONS Patients initiating insulin glargine rather than NPH do not seem to be at an increased risk for cancer. While our study contributes significantly to our evidence base for long-term effects, this evidence is very limited mainly based on actual dynamics in insulin prescribing.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816915/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454779
Collections
- HMS Scholarly Articles [17843]
Contact administrator regarding this item (to report mistakes or request changes)